Imperial College London

DrNicholasKirkby

Faculty of MedicineNational Heart & Lung Institute

Senior Research Fellow
 
 
 
//

Contact

 

+44 (0)20 7594 7922n.kirkby

 
 
//

Location

 

364Sir Alexander Fleming BuildingSouth Kensington Campus

//

Summary

 

Overview

Dr Kirkby's current work centres around the role of cyclo-oxygenase and related enzyme pathways in cardiovascular disease, cancer, inflammation and immunology and is supported by close collaboration with colleages at NHLI and international leaders in the field. 

COX-1 in the vasculature

COX isoform expression in human aortic endothelial cells

COX isoform expression in human aortic endothelial cells

COX-1 is ubiquitously expressed throughout the vasculature and in platelets. It is clear that COX-1 in platelets drives thrombosis, and inhibition of this explains the cardioprotective effects of aspirin. The role of COX-1 in the vasculature, however, remains less clear with some in vitro evidence suggesting that vascular COX-1 may have both harmful and protective roles in the cardiovascular system. Now, we are using unique genetic models of vascular COX-1-deficiency to explore the relative importance of these effects in vivo. The aim of this work is not only to clarify the role of vascular COX-1 in cardiovascular health and disease but also to test the idea that targeting COX-1 in blood vessels as well as platelets could improve the therapeutic effects of aspirin. This work is performed in collaboration with Prof Harvey Herschman at UCLA and is supported by a BHF Intermediate Research Fellowship.

Cardiovascular side effects of NSAIDs

COX-2 deletion increases atherosclerosis

COX-2 deletion increases atherosclerosis

Non-steroidal anti-inflammatory drugs (NSAIDs), which work by inhibition of COX-2, are amongst the most widely used drugs worldwide. However, their use is associated with rare but serious cardiovascular side effects including heart attacks and strokes. This has prevented development of new NSAID-like drugs, including for cancer prevention, where NSAIDs have proven benefits. We are taking an unbiased systems biology approach to this question, to identify new COX-2 regulated mechanisms that can explain cardiovascular toxicity of NSAIDs and biomarkers that can predict those individuals sensitive to these effects. Using this approach we have recently identified one candidate molecule as ADMA, an endogenous inhibitor of the cardioprotective NO pathway, which is elevated in people taking NSAIDs and which could explain their cardiovascular toxicity and/or predict those at risk. Most recently, we have created novel lines of renal and vascular specific COX-2 knockout mice to determine the relative roles of these tissues in COX-2 cardiovascular protection. This work is performed in collaboration with Prof Jane Mitchell at Imperial College and is supported by a BHF programme grant.

Rgl1 in NSAID pharmacology

Another lead we have identified from global gene expression profiling of COX-2 knockout tissue is Rgl1. Rgl1 is a component of the Ras pathway which is activated by Ras and activates Ral, leading to various biological effects. This pathway is most commonly implicated in cancer development, but also plays crucial roles in inflammatory and vascular responses. We have observed that Rgl1 is down-regulated by COX-2 deletion in vivo and COX-2 inhibition in vitro and are currently studying whether this is relevant to the therapeutic or side effects of NSAID drugs which inhibit COX-2. Most importantly, we are studying whether Rgl1 down-regulation can explain the known anti-cancer effects of these drugs. We are now studying these questions using a unique Rgl1-deficient mouse model.

Mechanisms of COX-2 expression

Patterns of constitutive COX-2 expression in healthy tissues

Patterns of constitutive COX-2 expression in healthy tissues

COX-2, the target of NSAID drugs, is typically though of as an inducible enzyme,  not present in healthy tissues but is specifically unregulated during inflammation and cell growth. However, it is becoming increasingly clear that COX-2 can also be expressed constitutively, and that is constitutive rather than induced COX-2 that explains cardiovascular and gastrointestinal side effects of NSAIDs. We have performed systematic mapping of constitutive COX-2 expression and are currently exploring the mechanisms that drive COX-2 expression in healthy tissues with the idea that targeting COX-2 at the transcriptional level could dissociate therapeutic and side effects of COX-2 inhibition. In addition, we are exploring how different types of inflammatory stimuli modulate COX-2 expression and the implications this has for specific immunological functions.

Platelets and eicosanoids

Impaired platelet adhesion in a patient lacking eicosanoids

Impaired platelet adhesion in a patient lacking eicosanoids

Eicosanoids are crucial signaling molecules generated by platelets and the vasculature that control platelet activation. While many of these, such as thromboxane and prostacyclin, are well understood many questions remain over how they interact with anti-platelet drugs, with other cell types and with the hundreds of related lipid mediators produced in parallel.  Using traditional pharmacological approaches and samples from a unique cPLA2-deficient patient whose platelets cannot synthesise eicosanoids, we are currently studying how the full range of platelet eicosanoids act together to regulate platelet function, and how vascular eicosanoids interact with anti-platelet drugs to control platelet reactivity. This work is performed in collaboration with Prof Tim Warner, Queen Mary University.

MRes & PhD students

show research

Current


Mr Jake Samuel (MRes Biomedical Research course) - ''Evidence linking gastrointestinal COX-2 expression with cardiovascular protection'

Mr Yaniss Hamiche (MSc Novel Therapeutics course) - 'Mechanisms of paracetamol-induced cardio-renal toxicity'

Ms Aleksandra Judina (PhD candidate) - 'The role of cellular microdomains in prostacyclin pharmacology in cardiac myocytes'

Dr Ricky Vaja (Clinical Fellow/PhD candidate) - 'An -omics approach to identifying biomarkers of NSAID cardiovascular toxicity'


Previous


Ms Sarah Mazi (PhD)- completed October 2018

Ms Malak Al-Yamani (PhD) - completed June 2016

Dr William Wright (PhD) - completed Dec 2014

Mr Andrew Ravendren (BSc)

Ms Xingzhi Cheng (MRes)

Ms Lulu Wang (MRes)

Mr Andreas Perikleous (MSc) - completed Sept 2019

Ms Eleanor Stafford (MSc) - completed Sept 2019

Ms Rachel Loy (BSc) - completed Sept 2019

Mr Mohammed Qader (MRes) - completed Sept 2019

Ms Asia Begum (MRes)  completely Sept 2019

Ms Ami Vadgama (MSc) - completed Sept 2018

Mr Youssef Elghazouli (MRes) - completed Sept 2018

Mr Lasitha Dolamulla (MRes) - completed Sept 2018

Ms Sarah McCann (MRes) - completed Sept 2017

Ms Ioanna Papacharalampous (MSc) - completed Sept 2017

Mr Joshua Benson (MRes) - completed Sept 2017

Mr George Galaris (MRes) - completed Sept 2016

Ms Anitha Nair (MRes) - completed Sept 2016

Ms Katie Anders (MRes) - completed Sept 2016

Mr Sami Jora (MRes) - completed Sept 2015

Mr Bosun Buraimoh (MRes) - completed Sept 2015

Ms Stefania Mataragka (MRes) - completed Sept 2014

Ms Charlotte Cheadle (MRes) - completed Sept 2014

Ms Anna Middleton (MRes) - completed Sept 2014

Mr Philip Austin (MRes) - completed Sept 2013

Mr Oladipupo Adeyemi (MRes) - completed Sept 2012

Ms Nura Mohamed (MRes) - completed Sept 2012

 

Press Releases & News Items

show research